Fulltext

Prediction of Distant Metastasis in Head Neck Cancer Patients: Implications for Induction Chemotherapy and Pre-treatment Staging? = Voraussage der Metastasierungswahrscheinlichkeit bei Patienten mit Kopf-Hals-Tumoren: Implikationen für Induktionschemotherapie und Metastasen-Staging?

Studer, Gabriela ; Seifert, Burkhardt ; Glanzmann, Christoph

In: Strahlentherapie und Onkologie, 2008, vol. 184, no. 11, p. 580-585

Add to personal list
    Title
    • Prediction of Distant Metastasis in Head Neck Cancer Patients: Implications for Induction Chemotherapy and Pre-treatment Staging?
    Translated Title ()
    • Voraussage der Metastasierungswahrscheinlichkeit bei Patienten mit Kopf-Hals-Tumoren: Implikationen für Induktionschemotherapie und Metastasen-Staging?
    Author
    • Studer, Gabriela. Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland
    • Seifert, Burkhardt. Biostatistics Unit ISPM, University of Zurich, Zurich, Switzerland
    • Glanzmann, Christoph. Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland
    Document Type
    • Postprint
    OAI-PMH Identifier
    • oai:doc.rero.ch:321413
    Summary
    Background and Purpose: : Intensity modulated radiation therapy (IMRT) combined treatment approaches, surgical and radiodiagnostic advances, respectively, lead to improved local-regional control in head neck cancer (HNC). With increasing local-regional control, distant metastases (DM) become more meaningful. In some trials without concomitant chemotherapy, induction chemotherapy (IC) resulted in an absolute reduction of DM by ~10-15%. In order to define a more efficient selection of patients at risk for DM with respect to IC and M-staging, we analysed our patients treated by contemporary standards. Patients and Methods: : Between 1/2002 to 12/2007, 409 HNC patients were treated with IMRT; 303/409 (74%) underwent definitive, 106 (26%) postoperative IMRT. The mean/median follow-up was 23/20 months (3-72). 70% tolerated 4-7, 9% 1-3 cycles of simultaneous cisplatin. Treatment followed a prospectively designed protocol. In a previous study with 172 HNC IMRT patients, gross tumor volume (GTV) was found the strongest predictor for local-regional control. In the current study, this criterion has been prospectively tested for DM. Numbers needed to treat were calculated for IC. Results: : DM developed in 28/399 (7%) patients; 10 presented initially with DM (total 38/409). In 13/28 (46%), DM remained the only manifestation of disease. GTV was the strongest predictor for DM (p < 0.0001) of all tested. Only 4% of patients with GTV < 70 cc developed DM, vs. 25% (18/73) with > 70 cc; only 6 of them (6/73, 8%) developed isolated DM. Conclusion: : GTV was the most significant predictor for DM, that could guide selective pre-treatment M-staging. The subgroup with isolated DM in the high risk group, that could benefit from IC, is small